Keyphrases
Regadenoson
100%
Randomized Phase II Trial
100%
Sickle Cell Disease
100%
Phase II Trial
100%
Invariant Natural Killer T Cells
100%
Vaso-occlusive Crisis
100%
Receptor Agonist
42%
A2A Receptor
42%
Placebo
28%
T Cell Activation
28%
Placebo Groups
14%
Clinical Efficacy
14%
Randomized Placebo-controlled Trial
14%
Lymphocyte Subsets
14%
Length of Hospital Stay
14%
Pain Score
14%
Hospital Admission
14%
Primary Outcome Measure
14%
Plasma Concentration
14%
Anti-inflammatory Effect
14%
Tissue Inflammation
14%
Cell Samples
14%
Opioid Use
14%
Treatment Standards
14%
Hypoxia-reoxygenation
14%
Adenosine A2A Receptor Antagonist
14%
Medicine and Dentistry
Natural Killer T Cell
100%
Regadenoson
100%
Sickle-Cell Disease
100%
Receptor
57%
Placebo
57%
Infusion
42%
Patient with Sickle Cell Disease
42%
T Cell Activation
28%
Arm
14%
Lymphocyte Subpopulation
14%
Low Drug Dose
14%
Mediator
14%
Hypoxia
14%
Adenosine
14%
Antiinflammatory Activity
14%
Primary Outcome
14%
Pharmacology, Toxicology and Pharmaceutical Science
Sickle Cell Anemia
100%
Regadenoson
100%
Placebo
66%
Receptor Agonist
66%
Inflammation
16%
Adenosine
16%
Hypoxia
16%
Antiinflammatory Activity
16%
Neuroscience
T Cell
100%
Regadenoson
100%
Placebo
57%
Receptor Agonists
57%
Cell Activation
28%
Anti-Inflammatory
14%
Adenosine A2A Receptor
14%
Lymphocyte Subpopulation
14%
Blood Plasma
14%
Immunology and Microbiology
Natural Killer T Cell
100%
Sickle Cell
100%
Agonist
57%
T Cell Activation
28%
Mediator
14%
Low Drug Dose
14%
Lymphocyte Subpopulation
14%
Blood Level
14%
Arm
14%
Antiinflammatory Activity
14%
Reoxygenation
14%